French pharmaceutical company Servier is making a big bet that a tiny drugloaded implantable pump being developed by a Bostonbased startup will transform the global market for patients with diabetes  Servier has agreed to pay Intarcia Therapeutics Inc  million up front with potential additional payments that could increase the total to more than  billion for rights to codevelop the device for most markets outside the US the companies said Closely held Intarcia retains full rights to the treatment for the US
  